Search | Clinical Trials Finder

Conditions: Acne Vulgaris
Interventions: Winlevi (clascoterone) 1% & Adapalene 0.3% gel; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 12 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Plantar Fasciitis of Both Feet
Interventions: Lipiodol (ethiodized oil) injection; Device
Lead sponsor: IR Centers; Other
Eligibility: 22 Years to 100 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions: STRO-002; Drug
Lead sponsor: Sutro Biopharma, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 23
States / cities: Tucson, Arizona • Los Angeles, California • San Francisco, California + 19 more

Conditions: Psoriasis Vulgaris
Interventions: LEO 90100, Betamethasone plus calcipotriol, Ointment vehicle, LEO 90100 vehicle; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 39
States / cities: Hot Springs, Arkansas • Los Angeles, California • Oceanside, California + 30 more

Conditions: Plasma Cell Myeloma
Interventions: isatuximab SAR650984, lenalidomide, dexamethasone; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 5
States / cities: San Francisco, California • Tampa, Florida • St Louis, Missouri + 2 more

Conditions: Sexually Transmitted Diseases, Unsafe Sex, Substance-Related Disorders
Interventions: PACT, TAU; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Tobacco Use Disorder, Tobacco Smoking, Tobacco Dependence
Interventions: Cannabidiol (CBD) 800 mg, Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: North Hollywood, California

Conditions: Musculoskeletal Pain
Interventions: oxycodone/APAP, hydrocodone/APAP, codeine/APAP, 400 ibuprofen/APAP, 800 ibuprofen/APAP; Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 21 Years to 64 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Healthy
Interventions: MGL-3196, Pioglitazone 15mg; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Oesophageal Squamous Cell Carcinoma
Interventions: I-DXd, Rescue Medication; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Atrial Fibrillation
Interventions: Antiarrhythmic drug, Catheter ablation; Drug · Procedure
Lead sponsor: Valley Health System; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Ridgewood, New Jersey

Conditions: HIV Infections
Interventions: Truvada, Genvoya; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Epilepsy, Tuberous Sclerosis Complex, Focal Cortical Dysplasia
Interventions: Everolimus; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 2 Years to 40 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Phenylketonuria (PKU)
Interventions: BMN165 20mg/day, BMN165 40mg/day, Placebo; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 29
States / cities: La Jolla, California • Oakland, California • Aurora, Colorado + 26 more

Conditions: Primary Open Angle Glaucoma, Glaucoma, Primary Open Angle Glaucoma or Ocular Hypertension
Interventions: Direct Selective Laser Trabuloplasty; Device
Lead sponsor: Brian Shafer; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2026
U.S. locations: 1
States / cities: Plymouth Meeting, Pennsylvania

Conditions: Hearing Loss, Stress
Interventions: The Living Well with Hearing Loss Workshop, hearing aid services; Behavioral · Device
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 85 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Bay Pines, Florida • Portland, Oregon

Conditions: Cardiovascular Disease
Interventions: Integrative Therapies Intervention; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Non Insulin Dependent Diabetes, Pregnancy
Interventions: Metformin, Insulin; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Covid19
Interventions: Fluvoxamine, Placebo; Drug · Other
Lead sponsor: Susanna Naggie, MD; Other
Eligibility: 30 Years and older
Enrollment: 1,331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 91
States / cities: Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 79 more

Conditions: High Grade Upper Tract Urothelial Carcinoma
Interventions: Methotrexate, Vinblastine, Doxorubicin, Cisplatin, Gemcitabine, Carboplatin, Pegfilgrastim, Nephroureterectomy; Drug · Procedure
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 134
States / cities: Birmingham, Alabama • Aurora, Colorado • Colorado Springs, Colorado + 93 more

Conditions: Bipolar Disorder
Interventions: Metformin, healthy lifestyle intervention (LIFE); Drug · Behavioral
Lead sponsor: Melissa Delbello; Other
Eligibility: 8 Years to 19 Years
Enrollment: 1,565 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 29
States / cities: Covington, Kentucky • Neptune City, New Jersey • Amityville, New York + 13 more

Conditions: HIV Infections
Interventions: NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT), NNRTIs (EFV, NVP), PIs (AMP, IDV, LPV/r, NFV, SQV, RTV); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 30 Days to 18 Years
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 29
States / cities: Alhambra, California • Long Beach, California • Los Angeles, California + 22 more

Conditions: Hypothyroidism Primary
Interventions: Liothyronine (L-T3), Levothyroxine Sodium (LT4) Tablets, Liothyronine (LT3) placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Sacituzumab tirumotecan, Pemetrexed, Carboplatin, H1 Receptor Antagonist, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent); Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 17
States / cities: Oakland, California • Roseville, California • San Francisco, California + 13 more

Search by objective public record fields.

A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne

Embolization for the Treatment of Heel Pain Secondary to Plantar Fasciitis

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris

SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients

Protect and Connect: Couple HIV Prevention for Drug Involved Male Offenders

Cannabidiol for Reducing Cigarette Use

Comparing Five Oral Analgesics for Treatment of Acute Pain in the Emergency Department (ED)

Drug Interaction Study of MGL-3196 With Pioglitazone

A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)

Catheter Ablation for Recently Diagnosed Paroxysmal Atrial Fibrillation

Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities

A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD

Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU

A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients

Clinical Trial of the "Living Well With Hearing Loss Workshop"

Usefulness of Integrative Medicine Tools As Adjunctive Care for Women After Coronary Artery Bypass Grafting

Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm B (Fluvoxamine)

Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer

Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs

Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children

T4/T3 Therapy in Hypothyroidism

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)